Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

December 31, December 31,

2007 2006

ASSETS (Note 1)

Current assets:

Cash and cash equivalents $11,726,126 $6,075,449

Marketable securities 35,957,933 57,029,199

Prepaids and other current

assets 945,583 1,082,817

Total current assets 48,629,642 64,187,465

Property and equipment, net 4,238,498 4,728,929

Deposits and other assets 377,798 359,974

Total assets $53,245,938 $69,276,368

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and other

accrued liabilities $4,515,426 $3,439,422

Accrued compensation 2,225,868 2,323,742

Current portion of deferred

revenue 1,227,031 2,260,478

Current portion of equipment

financing 953,940 885,273

Total current liabilities 8,922,265 8,908,915

Non-current portion of deferred

revenue - 1,143,159

Non
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... 2014 Market Research Report ... and in-depth research report on the Polyacrylamide ... including Polyacrylamide definition, classification, application, and industry ... This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic ...
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... A major challenge before new biotechnology start-up ... of Boston-Cambridge, is gaining visibility that can lead to ... Director of Boston’s Adult Stem Cell Technology Center, LLC ... of his company an important priority since he started ... a social media marketing campaign launched earlier ...
Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... 3 Ikaria Holdings, Inc., a fully,integrated critical ... CEO, David Shaw, will present at the 26th ... at 3:00 p.m., PST. The,conference will be held ... in San,Francisco., About Ikaria Holdings, Inc., ...
... than 500,000 Total Prescriptions Have Been Dispensed for ... ... 3 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: SHQ), the ... from the U.S. Food and Drug,Administration (FDA) for three additional ...
... Jan. 3 Neogen Corporation,(Nasdaq: NEOG ) announced ... FY 2008, which ended Nov. 30, increased 34% from ... split, net income in the,quarter rose to $0.22 per ... net income of $3,254,000 set another quarterly,record for the ...
Cached Biology Technology:FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 2FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 3FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 4FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients 5Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5
(Date:9/1/2014)... decisions of the Nomenclature Section of the XVIII International ... 2011. This meeting is held every six years and ... rules for naming algae, fungi and plants get together ... the organisms they study. This is the primary product ... algae, fungi, and plants, which was published in 2012. ...
(Date:8/31/2014)... fast and accurate tool to diagnose tuberculosis in ... developed test (TAM-TB assay) is the first reliable ... The test features excellent specificity, a similar sensitivity ... a blood test. The promising findings are a ... children, particularly in tuberculosis-endemic regions. , The study ...
(Date:8/31/2014)... of the greatest challenges in modern medicine is developing ... with minimal toxicity and side-effects to the patient. Such ... the drug molecule. Ideally, the drug should have a ... so that it binds it with high specificity. Publishing ... a synthetic amino acid that can impact the 3D ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2New tuberculosis blood test in children is reliable and highly specific 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... WORCESTER, Mass. Orthopedic surgeons are often hamstrung ... bone injuries resulting from trauma, aging or cancer. Conventional ... or brittle ceramics, and cannot readily conform to the ... in addition, they often require metallic fixation devices that ...
... Swiss needle cast epidemic in Douglas-fir forests of the coastal ... over at least the past 100 years, and is probably ... and a warmer climate, new research concludes. Scientists in ... found that this disease, which is affecting hundreds of thousands ...
... the University of Alabama at Birmingham (UAB) have been ... Scholarship and Excellence in Education Foundation. Atbin Doroodchi, ... Biology and Mathematics. He has a 3.95 grade-point average ... Honors Program. Doroodchi is an undergraduate researcher in the ...
Cached Biology News:Smart orthopedic implants and self-fitting tissue scaffolding created by UMMS researchers 2Forest epidemic is unprecedented phenomenon, still getting worse 2Forest epidemic is unprecedented phenomenon, still getting worse 3Forest epidemic is unprecedented phenomenon, still getting worse 43 UAB students awarded prestigious Goldwater scholarships 2
... SYBR Green II RNA gel ... gel stain that has bright fluorescence when ... gels, making it ideal for use with ... scanners or standard UV transilluminators. A 500 ...
... records analyzes and reports the data from any ... the a chart recorder. The final data is ... The end-point selection is automatic for Systolic, Mean, ... computed. The user is always in the position ...
... is taking automated patch clamping to a new ... to generate thousands of high quality data points ... in ion channel drug discovery and safety testing. ... afforded by conventional patch clamping can now be ...
... Reagents for the differentiation of mouse ... cell bodies exist in the midbrain, where ... nigra, the ventral tegmental area, and the ... rise to extensive forebrain dopamine innervation ( ...
Biology Products: